Histomorphometric and immunohistochemical assessment of RUNX2 and VEGF of Biogran™ and autogenous bone graft in human maxillary sinus bone augmentation: A prospective and randomized study

Página do item simplificado
dc.contributor.authorPereira, Rodrigo dos Santos [UNESP]
dc.contributor.authorMenezes, Juliana Dreyer [UNESP]
dc.contributor.authorBonardi, João Paulo [UNESP]
dc.contributor.authorGriza, Geraldo Luiz [UNESP]
dc.contributor.authorOkamoto, Roberta [UNESP]
dc.contributor.authorHochuli-Vieira, Eduardo [UNESP]
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2018-12-11T17:32:49Z
dc.date.available2018-12-11T17:32:49Z
dc.date.issued2017-10-01
dc.description.abstractBackground: Few studies have been conducted to assess new bone formation using Biogran, a bioactive glass, in maxillary sinus bone augmentation through a prospective and randomized evaluation. Moreover, there are no studies that evaluate cellular behavior by immunohistochemical assessment for osteoblastic and vascular activity during bone repair. Purpose: The aim of this study is to compare new bone formation and cellular behavior with Biogran alone, a 1:1 combination of Biogran and autogenous bone graft, and autogenous bone graft alone in human maxillary sinuses. Materials and methods: Ten maxillary sinuses were grafted with Biogran (Group 1), 10 grafted with Biogran added to autogenous bone graft in a 1:1 ratio (Group 2), and 10 grafted with autogenous bone graft alone (Group 3). After 6 months of bone healing, samples were obtained concurrent to the dental implants' placement to be evaluated by histomorphometric and immunohistochemical assessment for RUNX2 and vascular endothelial growth factor (VEGF). Results: The amount of new bone formation in Group 1 was 42.0 ± 7.3% in the pristine bone region, 40.7 ± 14.0% in the intermediate region, and 45.6 ± 13.5% in apical region. In Group 2, for pristine bone, intermediate, and apical regions, new bone formation was 36.6 ± 12.9%, 33.2 ± 13.3%, and 45.8 ± 13.9%, respectively. Group 3 showed new bone formation of 37.3 ± 11.6%, 35.3 ± 14.7%, and 39.9 ± 15.8% in pristine bone, intermediate, and apical regions, respectively. The immunolabeling for RUNX2 showed low cellular activity in osteoblasts for all groups, and the VEGF assessment demonstrated moderate cellular activity in Groups 1 and 2; however, Group 3 presented with low activity in the pristine bone region, followed by moderate activity in the intermediate and apical region. Conclusion: This study demonstrates that Biogran and its combination with autogenous bone graft 1:1 are good bone substitutes due to their similarity to autogenous bone graft.en
dc.description.affiliationUniversidade Estadual Paulista – UNESP Surgery and Integrated Clinic Department
dc.description.affiliationUnespUniversidade Estadual Paulista – UNESP Surgery and Integrated Clinic Department
dc.format.extent867-875
dc.identifierhttp://dx.doi.org/10.1111/cid.12507
dc.identifier.citationClinical Implant Dentistry and Related Research, v. 19, n. 5, p. 867-875, 2017.
dc.identifier.doi10.1111/cid.12507
dc.identifier.issn1708-8208
dc.identifier.issn1523-0899
dc.identifier.scopus2-s2.0-85020464425
dc.identifier.urihttp://hdl.handle.net/11449/178943
dc.language.isoeng
dc.relation.ispartofClinical Implant Dentistry and Related Research
dc.relation.ispartofsjr1,827
dc.rights.accessRightsAcesso restrito
dc.sourceScopus
dc.subjectbioactive glass
dc.subjectbiomaterials
dc.subjectbone substitutes
dc.subjectmaxillary sinus floor elevation
dc.titleHistomorphometric and immunohistochemical assessment of RUNX2 and VEGF of Biogran™ and autogenous bone graft in human maxillary sinus bone augmentation: A prospective and randomized studyen
dc.typeArtigo
unesp.author.lattes6853485483683678[6]
unesp.author.orcid0000-0003-4040-9313[6]

Arquivos

Coleções

Artigos - Ciências Básicas - FOA